| Patient . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . |
|---|---|---|---|---|---|---|---|---|---|
| Age | 6 mo | 7 y | 1 mo | 2 y | 16 y | 10 mo | 3 wk | 6 mo | 4 mo |
| Sex | M | M | F | M | M | F | F | F | F |
| Comorbid conditions | Immune- deficiency | Leukemia HSCT | Malignancy | Cirrhosis | Congestive heart failure | Pulmonary disease | Pulmonary disease | None | None |
| Hospital days until positive culture | 17 | 53 | 28 | 1 | 0 | 11 | 23 | 19 | 21 |
| Preceding antibiotics (total days) | CTX (2) CFP (8) TZP (4) AMP (7) | CTX (3) CFP (14) MEM (4) | SXT (26) TZP (8) MEM (5) | TZP (1) | None | None | None | SAMa | CTXa |
| Culture source | Respiratory | Urine | Respiratory | Blood | Abdominal | Respiratory | Blood | Respiratory | Respiratory |
| Infection | Colonization | Infection | Infection | Infection | Infection | Infection | Infection | Infection | Infection |
| Species | Klebsiella pneumoniae | Enterobacter spp | Klebsiella pneumoniae | Klebsiella pneumoniae | Klebsiella pneumoniae | Proteus mirabilis | Klebsiella pneumoniae | Enterobacter spp | Enterobacter spp |
| Carbapenemase | NDM-1 | Non-CP CRE | KPC-2 | OXA-232 | Non-CP CRE | KPC negative | KPC-2 | Not tested | KPC negative |
| Antibiotic therapy for 30 d after culture (total days) a unkown | CFP (3) MEM (17) CST (11) PMB (1) | MEM (21) CIP (11) | PMB (1) CZA (7) MEM (3) SXT (7) | MEM (5) TOB (2) AMK (2) CZA (6) CST (5) SXT (6) | CFP (1) | TZPa | CST (3) | GEN (6) MEM (4) | GEN (3) |
| Days from positive culture to death | 16 | 50 | 8 | 9 | 1 | 12 | 4 | 57 | 30 |
| Patient . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . |
|---|---|---|---|---|---|---|---|---|---|
| Age | 6 mo | 7 y | 1 mo | 2 y | 16 y | 10 mo | 3 wk | 6 mo | 4 mo |
| Sex | M | M | F | M | M | F | F | F | F |
| Comorbid conditions | Immune- deficiency | Leukemia HSCT | Malignancy | Cirrhosis | Congestive heart failure | Pulmonary disease | Pulmonary disease | None | None |
| Hospital days until positive culture | 17 | 53 | 28 | 1 | 0 | 11 | 23 | 19 | 21 |
| Preceding antibiotics (total days) | CTX (2) CFP (8) TZP (4) AMP (7) | CTX (3) CFP (14) MEM (4) | SXT (26) TZP (8) MEM (5) | TZP (1) | None | None | None | SAMa | CTXa |
| Culture source | Respiratory | Urine | Respiratory | Blood | Abdominal | Respiratory | Blood | Respiratory | Respiratory |
| Infection | Colonization | Infection | Infection | Infection | Infection | Infection | Infection | Infection | Infection |
| Species | Klebsiella pneumoniae | Enterobacter spp | Klebsiella pneumoniae | Klebsiella pneumoniae | Klebsiella pneumoniae | Proteus mirabilis | Klebsiella pneumoniae | Enterobacter spp | Enterobacter spp |
| Carbapenemase | NDM-1 | Non-CP CRE | KPC-2 | OXA-232 | Non-CP CRE | KPC negative | KPC-2 | Not tested | KPC negative |
| Antibiotic therapy for 30 d after culture (total days) a unkown | CFP (3) MEM (17) CST (11) PMB (1) | MEM (21) CIP (11) | PMB (1) CZA (7) MEM (3) SXT (7) | MEM (5) TOB (2) AMK (2) CZA (6) CST (5) SXT (6) | CFP (1) | TZPa | CST (3) | GEN (6) MEM (4) | GEN (3) |
| Days from positive culture to death | 16 | 50 | 8 | 9 | 1 | 12 | 4 | 57 | 30 |
Abbreviations: AMK, amikacin; CFP, cefepime; CIP, ciprofloxacin; CST, colistin; CZA, ceftazidime; GEN, gentamicin; MEM, meropenem; PMB, polymyxin B; TOB, tobramycin; TZP, piperacillin-tazobactam; SAM, sulbactam-ampicillin; SXT, trimethoprim-sulfamethoxazole.
aDuration of therapy unknown.
| Patient . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . |
|---|---|---|---|---|---|---|---|---|---|
| Age | 6 mo | 7 y | 1 mo | 2 y | 16 y | 10 mo | 3 wk | 6 mo | 4 mo |
| Sex | M | M | F | M | M | F | F | F | F |
| Comorbid conditions | Immune- deficiency | Leukemia HSCT | Malignancy | Cirrhosis | Congestive heart failure | Pulmonary disease | Pulmonary disease | None | None |
| Hospital days until positive culture | 17 | 53 | 28 | 1 | 0 | 11 | 23 | 19 | 21 |
| Preceding antibiotics (total days) | CTX (2) CFP (8) TZP (4) AMP (7) | CTX (3) CFP (14) MEM (4) | SXT (26) TZP (8) MEM (5) | TZP (1) | None | None | None | SAMa | CTXa |
| Culture source | Respiratory | Urine | Respiratory | Blood | Abdominal | Respiratory | Blood | Respiratory | Respiratory |
| Infection | Colonization | Infection | Infection | Infection | Infection | Infection | Infection | Infection | Infection |
| Species | Klebsiella pneumoniae | Enterobacter spp | Klebsiella pneumoniae | Klebsiella pneumoniae | Klebsiella pneumoniae | Proteus mirabilis | Klebsiella pneumoniae | Enterobacter spp | Enterobacter spp |
| Carbapenemase | NDM-1 | Non-CP CRE | KPC-2 | OXA-232 | Non-CP CRE | KPC negative | KPC-2 | Not tested | KPC negative |
| Antibiotic therapy for 30 d after culture (total days) a unkown | CFP (3) MEM (17) CST (11) PMB (1) | MEM (21) CIP (11) | PMB (1) CZA (7) MEM (3) SXT (7) | MEM (5) TOB (2) AMK (2) CZA (6) CST (5) SXT (6) | CFP (1) | TZPa | CST (3) | GEN (6) MEM (4) | GEN (3) |
| Days from positive culture to death | 16 | 50 | 8 | 9 | 1 | 12 | 4 | 57 | 30 |
| Patient . | Patient 1 . | Patient 2 . | Patient 3 . | Patient 4 . | Patient 5 . | Patient 6 . | Patient 7 . | Patient 8 . | Patient 9 . |
|---|---|---|---|---|---|---|---|---|---|
| Age | 6 mo | 7 y | 1 mo | 2 y | 16 y | 10 mo | 3 wk | 6 mo | 4 mo |
| Sex | M | M | F | M | M | F | F | F | F |
| Comorbid conditions | Immune- deficiency | Leukemia HSCT | Malignancy | Cirrhosis | Congestive heart failure | Pulmonary disease | Pulmonary disease | None | None |
| Hospital days until positive culture | 17 | 53 | 28 | 1 | 0 | 11 | 23 | 19 | 21 |
| Preceding antibiotics (total days) | CTX (2) CFP (8) TZP (4) AMP (7) | CTX (3) CFP (14) MEM (4) | SXT (26) TZP (8) MEM (5) | TZP (1) | None | None | None | SAMa | CTXa |
| Culture source | Respiratory | Urine | Respiratory | Blood | Abdominal | Respiratory | Blood | Respiratory | Respiratory |
| Infection | Colonization | Infection | Infection | Infection | Infection | Infection | Infection | Infection | Infection |
| Species | Klebsiella pneumoniae | Enterobacter spp | Klebsiella pneumoniae | Klebsiella pneumoniae | Klebsiella pneumoniae | Proteus mirabilis | Klebsiella pneumoniae | Enterobacter spp | Enterobacter spp |
| Carbapenemase | NDM-1 | Non-CP CRE | KPC-2 | OXA-232 | Non-CP CRE | KPC negative | KPC-2 | Not tested | KPC negative |
| Antibiotic therapy for 30 d after culture (total days) a unkown | CFP (3) MEM (17) CST (11) PMB (1) | MEM (21) CIP (11) | PMB (1) CZA (7) MEM (3) SXT (7) | MEM (5) TOB (2) AMK (2) CZA (6) CST (5) SXT (6) | CFP (1) | TZPa | CST (3) | GEN (6) MEM (4) | GEN (3) |
| Days from positive culture to death | 16 | 50 | 8 | 9 | 1 | 12 | 4 | 57 | 30 |
Abbreviations: AMK, amikacin; CFP, cefepime; CIP, ciprofloxacin; CST, colistin; CZA, ceftazidime; GEN, gentamicin; MEM, meropenem; PMB, polymyxin B; TOB, tobramycin; TZP, piperacillin-tazobactam; SAM, sulbactam-ampicillin; SXT, trimethoprim-sulfamethoxazole.
aDuration of therapy unknown.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
